Association between tumor cell immunophenotype and involved FLC*
| Tumor cell immunophenotype* . | Normal FLC ratio, n (%) . | Abnormal FLC ratio, n (%) . | ||||
|---|---|---|---|---|---|---|
| Both normal . | Elevated κ . | Elevated λ . | Both elevated . | Involved κ . | Involved λ . | |
| κ (n = 26) | 9 (35) | 6 (23) | 0 (0) | 2 (7) | 9 (35) | 0 (0) |
| λ (n = 8) | 5 (63) | 0 | 1 (13) | 0 | 1 (13) | 1 (13) |
| Biclonal (n = 3) | 0 (0) | 1 (33) | 0 (0) | 1 (33) | 1 (33) | 0 (0) |
| Tumor cell immunophenotype* . | Normal FLC ratio, n (%) . | Abnormal FLC ratio, n (%) . | ||||
|---|---|---|---|---|---|---|
| Both normal . | Elevated κ . | Elevated λ . | Both elevated . | Involved κ . | Involved λ . | |
| κ (n = 26) | 9 (35) | 6 (23) | 0 (0) | 2 (7) | 9 (35) | 0 (0) |
| λ (n = 8) | 5 (63) | 0 | 1 (13) | 0 | 1 (13) | 1 (13) |
| Biclonal (n = 3) | 0 (0) | 1 (33) | 0 (0) | 1 (33) | 1 (33) | 0 (0) |
Percentages do not add up to 100 because of rounding of small numbers. P = .024 (Fisher exact test).
Immunophenotype defined in monoclonal B cells detected before CLL diagnosis.3